Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
Article Attribution | Read More at Article Source
The post Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims appeared first on RocketNews.